Physician profile
Kun Huang
NPI 1497744189
$6,062.65
in general payments reported to CMS, 2019-2025
31 companies · $599 in 2025
The $599 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $1,008 · 2021: $1,248 · 2022: $856 · 2023: $910 · 2024: $684 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,192.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,118.90 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $741.66 | 2019-2025 | Jardiance |
| Abbvie INC. | $514.87 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $491.83 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $478.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Gilead Sciences, INC. | $429.74 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $394.28 | 2019-2022 | |
| Glaxosmithkline, LLC. | $357.22 | 2019-2024 | Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $251.37 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $187.04 | 2023-2024 | Veozah |
| Dexcom, INC. | $126.29 | 2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $112.39 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $100.29 | 2021-2023 | |
| Radius Health, INC. | $98.29 | 2022-2023 | Tymlos |
| Merck Sharp & Dohme LLC | $87.31 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $80.93 | 2020-2021 | |
| Sanofi Pasteur INC. | $76.91 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $64.72 | 2022 | |
| Ironwood Pharmaceuticals, INC | $62.33 | 2019-2020 | |
| Seqirus USA INC | $37.31 | 2020-2025 | Flucelvax |
| Kyowa Kirin, INC. | $29.21 | 2022 | |
| Aimmune Therapeutics, INC. | $26.66 | 2025 | Zenpep |
| Boston Scientific Corporation | $25.46 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $24.88 | 2024 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $24.40 | 2022 | |
| Amarin Pharma, INC. | $23.68 | 2021 | |
| Exact Sciences Corporation | $22.91 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $21.21 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.85 | 2021 | |
| Novavax INC | $19.93 | 2024 | Novavax Covid-19 Vaccine, Adjuvanted |
| Allergan, INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kun Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.